Biomarker-based Algorithm for Diagnosis of Glioma (TELOGNOSTIC)

Civil Hospices of Lyon

Status: Unknown

Conditions: Glioma

Treatments: Other: PCR (Polymerase Chain Reaction)

Study type: Observational

Funder types: Other

Identifiers

NCT04194593

69HCL18_0795

Details and patient eligibility

About

ATRX (X-linked mental retardation and alpha-thalassaemia syndrome protein) loss and pTERT (Telomerase reverse transcriptase) mutation are diagnostic markers of gliomas. However, 4 to 28% of gliomas shows none of these alterations. The aim of this project is to propose a new test able to detect the telomeric status for every glioma. Based on this test and other markers (such as mutation of IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2)), investigators propose an algorithm, able to classify the main subtypes of gliomas (astrocytoma, oligodendroglioma and glioblastoma).

Enrollment: 300 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with a diagnosis of glioma (retrospective),
• Patient with available biological material : extracted DNA and/or FFPE tissue and/or frozen sample.
• Samples are not required any more for diagnosis purpose
• Patient with informed consent

Exclusion criteria

• Patient with no informed consent
• Patients with no available biological sample

Trial design

300 participants in 1 patient group

Glioma

Description:

FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)

Treatment:

Other: PCR (Polymerase Chain Reaction)